Biopharmaceutical News and Research

RSS

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.

12 Apr 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

7 Apr 2016

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics.

6 Apr 2016

Vanderbilt, Celgene collaborate to accelerate development of personalized therapies

Vanderbilt University Medical Center has entered into a strategic research agreement with Celgene Corporation, a biopharmaceutical company based in Summit, New Jersey.

5 Apr 2016

Beaumont urologists study use of enobosarm to treat women's SUI

Could a one-a-day pill be the answer for women with stress urinary incontinence - a condition resulting in leakage with coughing, sneezing and laughing?

30 Mar 2016

CCCBD offers promising new investigational therapy to treat childhood ALL

The Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles is one of the first sites in the world to offer a promising new investigational therapy to treat pediatric acute lymphoblastic leukemia (ALL).

30 Mar 2016

CRPS rank higher on pain scales than childbirth, cancer, amputation

Imagine pain in an arm or leg so intense that the sufferer would rather undergo an amputation than put up with it any longer. For those with complex regional pain syndrome (CRPS), this is not just a hypothetical nightmare—it is reality.

25 Mar 2016

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

14 Mar 2016

BioLineRx announces year end 2015 financial results, provides operational update

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015.

10 Mar 2016

Merck reports record results for 2015

Merck, a leading science and technology company, reported record results for 2015, emerging stronger from the transformation process that started in 2007. Net sales and EBITDA pre exceptionals were higher than ever before in Merck’s history of nearly 350 years.

From Merck 10 Mar 2016

Thermo Fisher exhibits new UHPLC-MS workflow solutions for biopharmaceutical characterization at Pittcon 2016

Biopharmaceutical companies can now achieve advanced levels of specificity, sensitivity and speed with specialized analytical workflow solutions for the characterization and quantification of proteins.

From Thermo Fisher Scientific Inc. 9 Mar 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

New report explores strategies involved in developing and commercializing FDC products

Fixed dose combination (FDC) products, which have been around for many years, can have both clinical and commercial advantages. Successful FDC products require thoughtful planning, beginning early in the product development and lifecycle management processes.

27 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2015.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona (IBB-UAB), in collaboration with the biopharmaceutical company SOM Biotech, located in the Barcelona Science Park (PCB), have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug, SOM0226 (tolcapone) that could significantly improve the pharmacological treatment of familial transthyretin amyloidosis (ATTR).

24 Feb 2016

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and full-year ended December 31, 2015 and provided a summary of recent corporate highlights.

23 Feb 2016

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.

22 Feb 2016

Researchers identify new group of powerful Ebola-fighting antibodies

A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus.

22 Feb 2016

Biopharmaceutical News and Research

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

Vanderbilt, Celgene collaborate to accelerate development of personalized therapies

Beaumont urologists study use of enobosarm to treat women's SUI

CCCBD offers promising new investigational therapy to treat childhood ALL

CRPS rank higher on pain scales than childbirth, cancer, amputation

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioLineRx announces year end 2015 financial results, provides operational update

Merck reports record results for 2015

Thermo Fisher exhibits new UHPLC-MS workflow solutions for biopharmaceutical characterization at Pittcon 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

New report explores strategies involved in developing and commercializing FDC products

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Regulus reports net loss of $7.2 million for fourth quarter 2015

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Researchers identify new group of powerful Ebola-fighting antibodies

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News